Navigation Links
CK Life Sciences Announces U.S. FDA's Clearance to Commence Phase III Clinical Testing of Melanoma Vaccine
Date:3/6/2012

HONG KONG, March 6, 2012 /PRNewswire-Asia/ -- CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company") today announced that the FDA (U.S. Food and Drug Administration) has granted clearance for its subsidiary Polynoma LLC ("Polynoma")'s Investigational new drug (IND) application, allowing it to proceed with Phase III clinical testing of its melanoma vaccine.

One of A Few Asian Companies Cleared by FDA for Phase III Clinical Trial

This makes CK Life Sciences one of a few Asian companies to obtain clearance from the FDA to commence Phase III clinical testing of a new drug.

"We are very delighted that the FDA has granted clearance for the Phase III clinical testing of our melanoma vaccine. We look forward to the positive results of the clinical trial, and the prospect of offering a new medicine for melanoma patients," said Mr. HL Kam, President and Chief Executive Officer of CK Life Sciences.

Melanoma Treatment in Demand

Malignant melanoma is the most serious form of skin cancer. An estimated 132,000 new cases of melanoma are diagnosed annually around the world, with about 76,000 in the United States alone. The melanoma market is estimated to be in excess of US$1 billion, with the United States and Europe being the major markets.

Melanoma is treated with a combination of surgery, radiation therapy, immunotherapy or chemotherapy, depending on the stage of the disease. Interferon alfa-2b is the only currently approved treatment in the United States and Europe to reduce the likelihood of recurrence after resection in melanoma patients at high risk of recurrence, but its limited efficacy and significant toxicity have restricted its use.

CK Life Sciences' Melanoma Vaccine Stimulates Immunity to Fight Cancer

Using a combination of antigens from three proprietary melanoma cell lines, Polynoma's melanoma vaccine is intended to stimulate the body's immune system to fight the cancer.

Preparation for the Phase III clinical trial is already underway, and it is expected that patient enrollment will commence within several months.

This latest development follows the approval Polynoma obtained from the FDA of a clinical trial protocol under a Special Protocol Assessment (SPA) agreement. An SPA is an agreement between the FDA and the applicant that a proposed protocol's design and analysis plan are acceptable to the FDA as support for potential future approval of a drug, biologic or vaccine, if the results of the clinical trial are positive. It is a process that can support the future registration and launching of the product.

Drug research and development requires extensive testing, involving multiple stages of compound screening as well as pre-clinical and clinical development (Phase I, II, III clinical trials) prior to approval and registration by health authorities such as the FDA. Phase III clinical testing is generally the last step before a drug can be submitted for approval for registration and sale, and involves the generation of controlled clinical trial results that are statistically significant and clinically relevant.

For enquiries, please call Mrs. Wendy Tong Barnes or Ms. Carolina Cheung of CK Life Sciences at +852-2122-2150.

About CK Life Sciences

CK Life Sciences Int'l., (Holdings) Inc. is a listed company on The Stock Exchange of Hong Kong Limited (stock code: 0775). Bearing the mission of improving the quality of life, the Company is engaged in the business of research and development, commercialisation, marketing and sale of health and agriculture related products. CK Life Sciences is a member of the Cheung Kong Group. For additional information, please visit www.ck-lifesciences.com.

About Polynoma LLC

Polynoma LLC is an oncology-focused biotechnology company based in the United States and is a subsidiary of CK Life Sciences. It is currently developing a therapeutic vaccine for the treatment of melanoma. In addition to melanoma, Polynoma is also planning to evaluate the effectiveness of the vaccine in other cancer indications. For additional information, please visit www.polynoma.com.


'/>"/>
SOURCE CK Life Sciences Int'l., (Holdings) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Walgreens has committed to provide ... and Washington, D.C. as part of ... was commended by shareholder advocacy organization As You Sow. ... Sow. "Many people hold on to unneeded drugs because they ... tragic consequences." --> Conrad MacKerron , Senior ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  NOIT™ Research ... a special "Gift of Change" campaign to assist needy ... For every such unit sold between February 10, 2016 ... unit to a needy family. The NOIT is an ... non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, as ... The puck drops at 6:00pm, but fans will have the opportunity to experience the ... The MEGA Heart will be located on Ford Thunder Alley and provide fans with ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 ... but would shift more of the cost burden to military beneficiaries. , MOAA’s ... in the defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... discuss how to improve care by making data on heart procedures public and ... Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
Breaking Medicine News(10 mins):